Published Online:8 Dec 2011https://doi.org/10.2217/ebo.11.331
Abstract:
THodgkin’s and non-Hodgkin’s lymphomas are malignancies of mature B and T cells, and include a heterogeneous group of diseases affecting over 75,000 individuals in the USA and 113,000 individuals in Europe annually [101,102]. The variability in clinical course ranges from indolent but incurable disease stretching over decades, to rapidly proliferating lymphomas with high lethality in untreated patients but with substantial curative potential with the prompt institution of therapy. Despite major gains in initial treatment options, lymphomas remain among the top ten causes of cancer mortality, and new agents continue to be needed. A major challenge to the development of new treatments is the high clinicopathologic variability of lymphomas, as reflected by the inclusion of several dozen unique subtypes in the most recent iteration of the WHO classification [1]. However, the recent observation that abnormalities of the PI3K/Akt/mTOR pathway is shared among several lymphomas is striking. This may suggest that PI3K/Akt/mTOR pathway is a recurrent pathogenetic lesion in lymphomas, and there is now both preclinical and clinical evidence that inhibition of the mTOR kinase is a valid target across numerous lymphoma subtypes.
References
- 1 et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th Edition). The International Agency for Research on Cancer, Lyon, France (2008) .
- 2 Clinical development of mTOR inhibitors: a focus on lymphoma . Rev. Recent Clin. Trials 2 , 103 – 110 (2007) .
- 3 Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era . Blood 117 , 26 – 38 (2010) .
- 4 Targeting the PI3K/AKT/mTOR pathway in non-Hodgkin’s lymphoma: results, biology, and development strategies . Curr. Oncol. Rep. 13 , 398 – 406 (2011) .
- 5 Utility of mTOR inhibition in hematologic malignancies . Oncologist 16 , 730 – 741 (2011) .
- 6 et al. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression . J. Biol. Chem. 279 , 2737 – 2746 (2004) .
- 7 et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma . J. Clin. Oncol. 23 , 5347 – 5356 (2005) .
- 8 et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a Phase 2 trial in the North Central Cancer Treatment Group . Cancer 113 (3) , 508 – 514 (2008) .
- 9 et al. Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma . J. Clin. Oncol. 27 , 3822 – 3829 (2009) .
- 10 et al. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma . Leukemia 25 , 341 – 347 (2011) .
- 11 et al. PILLAR-1: Preliminary results of a Phase II study of mTOR inhibitor everolimus in patients with mantle cell lymphoma (MCL) who are refractory or intolerant to bortezomib . Blood 145 (2) , 67 – 74 (2010) .
- 12 et al. A multi-center Phase II study (SAKK 36/06) of single agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Presented at: 52nd Annual Meeting of the American Society of Hematology. Orlando, FL, USA 10 Novemeber (2010) .
- 13 et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a Phase 2 study . Lancet Oncol. 12 , 361 – 368 (2011) .
- 14 et al. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP–eIF4E . Cancer Cell 17 , 249 – 261 (2010) .
- 15 et al. Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop . Leuk. Lymphoma 52 , 24 – 33 (2011) .
- 16 et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells . N. Engl. J. Med. 351 , 2159 – 2169 (2004) .
- 17 et al. Syk-dependent mTOR activation in follicular lymphoma cells . Blood 108 , 4156 – 4162 (2006) .
- 18 et al. Effect of PI3K- and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice . Br. J. Cancer 104 (7) , 1116 – 1125 (104) .
- 19 et al. Temsirolimus has activity in non-mantle cell non-Hodgkin’s lymphoma subtypes: The University of Chicago Phase II consortium . J. Clin. Oncol. 28 , 4740 – 4746 (2010) .
- 20 et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia . J. Clin. Oncol. 28 , 1408 – 1414 (2010) .
- 21 et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies . Clin. Cancer Res. 12 , 65 – 5173 (2006) .
- 22 et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling . Nature 403 , 503 – 511 (2000) .
- 23 Proliferation and survival of activated B cells requires sustained antigen receptor engagement and phosphoinositide 3-kinase activation . J. Immunol. 170 , 5851 – 5860 (2003) .
- 24 Aggressive lymphomas . N. Engl. J. Med. 362 , 1417 – 1429 (2010) .
- 25 Genomic and pathway connectivity analyses identify novel strategies to overcome mTOR inhibitor resistance in DLBCL . Presented at: 52nd Annual Meeting of the American Society of Hematology. Orlando, FL, USA 10 November (2010) .
- 26 Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin’s lymphoma cells through a mechanism involving Akt kinase and mTOR . J. Pathol. 205 , 498 – 506 (2005) .
- 27 et al. A rapamycin derivative (everolimus) controls proliferation through downregulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas . Blood 106 , 1801 – 1807 (2005) .
- 28 et al. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma . Am. J. Hematol. 85 , 320 – 324 (2010) .
- 29 Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways . Leukemia 24 , 13 – 21 (2010) .
- 30 et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a Phase 2 trial in the North Central Cancer Treatment Group . Cancer 113 , 508 – 514 (2008) .
- 31 et al. Everolimus in relapsed lymphomas. Presented at: European Hematology Association 4–7 June 2009 (Abstract) .
Website
- 101 The global burden of disease. www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/cancer-facts-figures-2011
- 102 Cancer facts and figures 2011. www.cancer.org
- 103 US National Institutes of Health. www.clinicaltrials.gov
